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Abstract 
The intracellular autophagic degradative pathway can play tumour suppressive or 
tumour promoting roles depending on the stage of tumour development. Upon 
starvation or targeting of oncogenic receptor tyrosine kinases (RTKs), autophagy is 
activated due to inhibition of PI3K/AKT/mTORC1 signalling pathway and promotes 
survival, suggesting that autophagy is a relevant therapeutic target in these settings. 
However, the role of autophagy in cancer cells where the PI3K/AKT/mTORC1 
pathway is constitutively active remains only partially understood. Here we report a 
role for PI3K-independent basal autophagy in regulation of RTK activation in 
colorectal cancer (CRC) cells. PI3K and RAS-mutant CRC cells display basal 
autophagy levels despite constitutive mTORC1 signalling, but fail to increase 
autophagic flux upon RTK inhibition. Inhibition of autophagy via knockdown of ATG7 
leads to decreased phosphorylation of several RTKs, in particular c-MET. 
Internalised c-MET colocalised with LC3-positive vesicles, but inhibition of autophagy 
did not affect c-MET intracellular localisation. Finally, autophagy inhibition led to a 
decrease in mTORC2-mediated phosphorylation of AKT and mTORC2 signalling 
was linked to the defect in c-MET phosphorylation. Overall, our findings reveal a bi-
directional relationship between RTKs and autophagy in CRC cells, with implications 
for our understanding of autophagy role in cancer cell signalling. 
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Introduction 
Macroautophagy (referred to hereafter as autophagy) is a conserved and tightly 
regulated catabolic self-renewal pathway that helps cells maintain their homeostasis 
and overcome stress stimuli. Autophagy mediates the degradation of cytoplasmic 
long-lived proteins and organelles into lysosomes via their previous engulfment into 
cytoplasmic double membrane vacuoles, called autophagosomes.1-4 Autophagy is 
present at basal levels (basal autophagy) in most cells and tissues and functions as 
a quality control mechanism for both proteins and organelles. Upon stress, such as 
nutrient/growth factor deprivation or cancer treatment, autophagy is upregulated in 
the cell providing nutrient and energy precursors to enable survival.5, 6 The 
PI3K/AKT/mTORC1 molecular pathway axis has been described as a master 
negative regulator of autophagy via its ability to control the initiation steps of this 
catabolic process.7-11 Apart from regulating autophagosome initiation, mTORC1 has 
been recently suggested to control later stages of the autophagic process and 
specifically autophagosome maturation in nutrient-replete conditions.12 However, it 
has been suggested that autophagy can be also regulated via mTOR-independent 
mechanisms.13-19  
Autophagy has been found to play an important albeit complex role in cancer 
initiation and progression. It has been suggested to hold a tumour suppressive 
function during early tumourigenesis,20-27 whereas it can also sustain cancer 
progression.28-36 Increased levels of basal autophagy have been found in a variety of 
cancer tissues including colorectal cancer (CRC), where autophagy supports tumour 
growth and confers tumour aggressiveness.31 
Autophagy is inhibited by oncogenic tyrosine kinases (OncTKs) and receptor tyrosine 
kinases (RTKs) via activation of the PI3K/AKT/mTORC1 and RAS/MAPK signalling.37 
In this respect, work from our group and others has shown that induction of 
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autophagy upon pharmacological targeting of OncTKs/RTKs promotes survival. In 
turn, pharmacological inhibition of autophagy potentiates OncTK/RTK targeted 
therapy.2, 28, 38-41 In particular, autophagy has been placed downstream of two RTKs 
with a known role in cancer, the Epidermal Growth Factor Receptor (EGFR)17, 19, 42-50 
and the Hepatocyte Growth Factor Receptor (HGFR), c-MET.51 EGFR has been 
suggested to regulate autophagy either directly17, 19 or indirectly through its 
downstream effectors. Both EGFR and c-MET have been proposed to play tumour-
promoting roles in CRC.52-56 Although autophagy acts as a pro-survival mechanism 
upon nutrient deprivation in CRC,57 it remains unclear whether its inhibition could 
potentiate RTK targeted therapy.  
Here, we provide insights into the relationship between autophagy and RTK 
activation in CRC cells. In most CRC cell lines analysed, autophagy is not induced 
upon RTK inhibition due to constitutive PI3K/AKT signalling. Accordingly, autophagy 
inhibition does not potentiate RTK targeted therapy, suggesting that concomitant 
RTK/autophagy targeting would be of limited efficacy in the clinic. Interestingly, CRC 
cells display detectable basal autophagic flux despite RAS and PI3K activation. 
Inhibition of basal autophagy affects tyrosine phosphorylation of several RTKs, in 
particular c-MET. Internalised c-MET colocalised with LC3-positive vesicles, but 
inhibition of autophagy did not affect c-MET intracellular localisation. The effect on c-
MET phosphorylation upon autophagy inhibition is functionally linked to decreased 
mTORC2 signalling. Overall, our findings suggest a previously unreported function of 
basal autophagy in the regulation of mTORC2 and RTK activation, with implications 
for our understanding of the role of autophagy in cancer cell signalling.  
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Results 
Autophagy is not induced upon RTK inhibition due to constitutive PI3K/AKT 
signalling in CRC cells 
Work from our lab and others has shown that autophagy is induced upon 
pharmacological targeting of OncTKs/RTKs in cancer cells due to inhibition of the 
PI3K/AKT/mTORC1 pathway and mediates survival.28, 39, 41, 42, 45, 46 We set out to 
further investigate the RTK-autophagy pathway in the context of CRC, where RTK 
signalling is a factor implicated in tumour development and is being targeted 
clinically. In particular, several agents targeting EGFR and other members of the 
ErbB family are currently being tested in CRC trials.55, 56, 58, 59 These include 
monoclonal antibodies that specifically bind to EGFR extracellular domain and 
tyrosine kinase inhibitors (TKIs), which target the intracellular tyrosine kinase domain 
of EGFR.60, 61 One could hypothesise that autophagy induction could mediate 
resistance to EGFR therapy, as previously shown in the context of BCR/ABL 
pharmacologically inhibition.28 Unlike in CML, activating mutations of PI3K and KRAS 
oncogenes are present in a significant proportion of CRC patients and are associated 
with resistance to EGFR targeted therapy and tumour aggressiveness.54, 62 
Constitutive PI3K signalling should inhibit autophagy via mTORC1 (ref 9), whereas 
KRAS mutations are predicted to either inhibit (via PI3K/mTORC1) or activate 
autophagy.37 As a result, we first investigated whether EGFR targeted therapy could 
induce autophagy in a panel of CRC cell lines in relation to KRAS and PI3K 
mutational status (Supplementary Figure 1a). We confirmed KRAS mutational status 
in isogenic HCT-116, DLD-1 and SW48 cells (Supplementary Figure 1a-b). CaCo2 
cells were found to be heterozygous for KRAS G12S point mutation and DiFi cells 
were KRAS WT (Supplementary Figure 1a-b). Regarding PIK3CA mutational status, 
CRC cell lines included in the panel were heterozygous for activating PIK3CA point 
mutations with the exception of CaCo2 and DiFi cells that were PIK3CA WT 
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(Supplementary Figure 1a and c). All cell lines were treated with two different 
Cetuximab concentrations and LC3B levels were detected by immunoblotting. We 
also included chloroquine (CQ) treatment, as this allowed us to measure autophagic 
flux.63 Only DiFi cells were found to induce moderate autophagy levels upon 
Cetuximab treatment at both concentrations examined (Figure 1a). DLD-1, HCT-116, 
SW48 both KRAS WT and mutant cells as well as CaCo2 cells failed to induce 
autophagy by Cetuximab treatment at any concentration examined (Figure 1b-e). 
Similar results were obtained by treating cells with the TKI Gefitinib or RNAi-
mediated EGFR downregulation (Supplementary Figure 2a-b). PI3K is a family of 
lipid kinases, which catalyse the phosphorylation of the 3-hydroxyl group of the 
inositol ring in phosphatidylinositols (Ptdlns). Class I PI3Ks are downstream effectors 
of RTKs and they generate phosphatidylinositol 3,4,5 tri-phosphate (PIP3) from 
phosphatidylinositol 4,5 bi-phosphate (PIP2) that recruits AKT protein kinase and 3-
phosphoinositide-dependent kinase 1 (PDK1) to the plasma membrane priming in 
that manner AKT/mTORC1 pathway activation.64 Rat sarcoma protein (RAS) is 
belonging to the large family of small GTPases, which switch constantly from an 
inactive GDP-bound state to an active GTP-bound state. RAS are activated in 
response to active RTK signalling and catalyse the activation of RAF protein, which 
in turn phosphorylates MEK that finally leads to the phosphorylation of ERK1/2 
proteins.65 Additionally, RAS can directly activate PI3K and in that manner regulate 
AKT/mTORC1 pathway.64 
As EGFR inhibition failed to induce autophagy in most CRC cell lines analysed, we 
hypothesised that treatment with the lysosomotropic autophagy inhibitor CQ would 
not affect sensitivity of CRC cells to Cetuximab with the potential exception of DiFi 
cells, which induced autophagy following EGFR targeted therapy. Indeed, CQ 
treatment did not sensitise cells carrying PI3K and/or KRAS mutations to Cetuximab 
treatment (Supplementary Figure 3a-d). Of note, autophagy inhibition by CQ was 
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found to only marginally potentiate Cetuximab treatment in DiFi cells (Supplementary 
Figure 3e). CQ treatment alone did not affect CRC cell growth in the majority of the 
cell lines examined (Supplementary Figure 3a-d). 
As constitutive PI3K signalling is expected to lead to mTORC1-dependent inhibition 
of autophagy, we next examined the activation status of the PI3K/AKT pathway upon 
Cetuximab treatment. We observed that the phosphorylation of S473 residue of AKT 
was not downregulated upon Cetuximab treatment in HCT-116, DLD-1 and CaCo2 
cells (Supplementary Figure 4b-d). More specifically, AKT phosphorylation levels 
were increased upon Cetuximab treatment in DLD-1 and HCT-116 cells, whereas 
they were reduced in DiFi cells (Supplementary Figure 4a). Overall, these data 
suggest a correlation between KRAS and/or PI3K/AKT activation and failure to 
induce autophagy in CRC cells. In summary, resistance to induce autophagy upon 
EGFR inhibition correlated with PI3K mutational status in CRC cell lines, with the 
exception of CaCo2 cells. 
In order to establish a link between AKT activation levels and autophagy induction 
upon Cetuximab treatment, we generated DiFi cells stably expressing myristoylated-
AKT (LXSN_myrAKT). myrAKT protein is localised to the plasma membrane and 
remains constitutively active.18, 66 As expected, cells overexpressing myrAKT 
displayed higher pAKT levels at both steady state and upon Cetuximab treatment 
(Supplementary Figure 4e). Increased activation levels of AKT in LXSN_myrAKT DiFi 
cells resulted in lower autophagy induction levels upon Cetuximab treatment when 
compared with control DiFi cells (Supplementary Figure 4e), implying a functional link 
between AKT activation status and autophagy induction in CRC cells upon 
Cetuximab treatment.  
We next tested whether the use of the AKT vIII inhibitor could de-repress autophagy 
in PIK3CA-mutated cells following Cetuximab treatment. We found that AKT vIII 
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inhibitor alone or in combination with Cetuximab was able to downregulate pAKT 
levels compared to untreated or Cetuximab-only treated E545K and D549N PIK3CA 
mutant DLD-1 KRAS WT and mutant cells (Supplementary Figure 4f). Critically, in 
the conditions where pAKT levels were abolished, autophagy was induced upon AKT 
vIII inhibitor treatment alone or in combination with Cetuximab.  
Overall, our findings indicate that PI3K and KRAS mutations make CRC cells 
refractory to autophagy induction upon RTK inhibition due to constitutive activation of 
the PI3K/AKT pathway. 
 
Inhibition of PI3K-independent basal autophagic flux negatively affects RTK 
phosphorylation in CRC cells 
We noted that CRC cells were found to have basal levels of autophagy in 
unstimulated conditions (Figure 1f-i). In particular, the basal autophagic flux was 
independent of KRAS and PIK3CA mutational status, as both KRAS WT and KRAS 
mutant isogenic cell lines as well as PIK3CA WT (CaCo2 and DiFi) and PIK3CA 
mutant (HCT-116 and DLD-1) CRC cell lines displayed increased LC3-II/LC3-I ratio 
following CQ treatment (Figure 1f-i). We hypothesised that autophagy might not play 
a significant degradative role in CRC cells under basal conditions. In this respect, 
levels of p62, an autophagy adaptor involved in targeting of polyubiquitinated 
proteins and organelles for lysosomal degradation through binding LC3 on 
phagophore membranes, were examined. Inhibition of autophagic flux results in 
accumulation of p62 levels.67 However, in CRC cells p62 levels were not significantly 
affected by either CQ or inhibition of autophagy via a doxycycline (Dox)-inducible 
shRNA against ATG7, an essential autophagy gene (Supplementary Figure 5a-c). 
Based on these findings, we thought to investigate whether basal autophagy could 
affect cell signalling in fed-conditions as previously reported.68, 69 Specifically, we set 
out to investigate whether autophagy suppression could impact on RTK activation, 
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given the key role of RTKs in CRC pathogenesis. To this end, we utilised a phospho-
RTK array to evaluate the phosphorylation of 49 different RTKs. Activated KRAS 
G13D isogenic cell lines were also included in this examination in order to assess 
whether the presence of oncogenic KRAS affects autophagy-dependent RTK 
regulation. Interestingly, phosphorylation of eight different RTKs was decreased upon 
autophagy suppression in HCT-116 KRAS WT cells (Figure 2a-b). In particular, 
autophagy-compromised cells displayed a decrease in phosphorylation levels of the 
highly activated RTKs: i) c-MET (35%), member of HGFR RTK family; ii) Dtk (35%), 
member of AXL RTK family; iii) c-Ret (60%), member of the RET RTK family and iv) 
RYK (40%). In the same cells, RTKs with lower phosphorylation levels were also 
affected, such as TrkC (90%), EphA1 (46%), EphA2 (30%) and EphB2 (60%). 
Overall, autophagy inhibition led to reduced phosphorylation of 8 out of 49 RTKs 
included in the array. RTK phosphorylation was also affected in autophagy-
suppressed KRAS G13D HCT-116 cells: c-Ret (60%), c-Met (47%), MSP receptor 
(42%), EphA10 (38%), Dtk (30%), Insulin Receptor (26%), IGF-I receptor (22%), Axl 
(17%) and ROR2 (15%) (Figure 2a and c). In contrast to HCT-116 KRAS WT cells, 
autophagy suppression resulted in upregulated phosphorylation of TrkC RTK (~70%) 
in the presence of the KRAS G13D mutation (Figure 2a-c). To exclude a cell type-
specific effect of autophagy suppression, DLD-1 KRAS WT and G13D cells were 
also examined for RTK activation levels upon autophagy suppression. In accordance 
with the reduced RTK-phosphorylation phenotype observed in HCT-116 autophagy-
compromised cells, both DLD-1 KRAS WT and G13D autophagy-compromised cells 
displayed a decrease in phosphorylation of several RTKs (Supplementary Figure 6a-
c). 
In conclusion, autophagy suppression reduced phosphorylation of several RTKs in 
CRC cells, in most cases independently of KRAS mutational status.  
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Inhibition of basal autophagy downregulates c-MET phosphorylation  
We decided to focus on c-MET since it has been proposed to play an oncogenic role 
in CRC52 and it has been implicated in the development of primary and acquired 
resistance of mCRC cells and patients to EGFR-targeted therapy.53, 54 In line with the 
phospho-RTK array results, immunoprecipitated total c-MET was found to be less 
phosphorylated in autophagy-compromised cells compared to autophagy-proficient 
HCT-116 KRAS WT cells (Figure 3a). In contrast, phosphorylation levels of both IGF-
I R and EGFR were not affected following basal autophagy suppression, confirming 
results of the phospho-RTK array (Supplementary Figure 7a-b). Of note, total 
tyrosine-phosphorylation levels were not altered upon autophagy suppression 
(Figure 3a and Supplementary Figure 7a-b). We further confirmed that basal 
autophagy suppression reduces phosphorylation of c-MET using a phospho-specific 
c-MET antibody. The ratio between phosphorylated c-MET and total c-MET was 
decreased in total cell lysates from autophagy-compromised HCT-116 KRAS WT 
and G13D cells by approximately 40% and 30%, respectively (Figure 3b). 
Phosphorylation of c-MET was consistently reduced in HCT-116 cells where ATG7 
was knocked out using CRISPR/Cas9 technology (Figure 3c) and in autophagy-
compromised CaCo2 cells (Figure 3d). Total c-MET levels were unaltered in 
autophagy-compromised and autophagy-deficient cells (Figure 3b-d). Although 
autocrine c-MET activation in cancer has been previously described,70 we failed to 
detect any differences in HGF expression in lysates from ATG7 and LC3B 
knockdown cells (Supplementary Figure 7c). 
c-MET colocalises with LC3B positive intracellular structures but autophagy 
suppression does not alter c-MET localisation 
Evidence from the literature suggests that RTKs colocalise with autophagic 
structures, thus suggesting that autophagy may regulate c-MET by controlling its 
internalization or intracellular function.71, 72 To explore this, HCT-116 cells were 
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examined for endogenous c-MET and LC3B protein localisation using confocal 
microscopy. To increase the chances of detecting autophagosomes, we added CQ, 
which prevents their fusion with lysosomes and subsequent degradation.63 After CQ 
treatment c-MET was observed in punctate intracellular structures around the 
nucleus that colocalised with LC3B only in autophagy-proficient conditions (Figure 
4a). To determine whether this colocalisation pattern applied to another RTK, 
localisation of EGFR was examined upon CQ treatment in HCT-116 KRAS WT cells. 
It was observed that in contrast to c-MET, EGFR did not accumulate in perinuclear 
areas upon CQ treatment and no colocalisation with LC3B was observed (Figure 4b). 
We additionally investigated whether basal autophagy suppression is affecting 
localisation of c-MET and in that manner c-MET phosphorylation. To this end, we 
treated autophagy-proficient and -compromised HCT-116 cells with 10μM CQ and 
monitored c-MET localisation using confocal microscopy for endogenous c-MET. It 
was found that basal autophagy suppression did not change intracellular c-MET 
accumulation (Figure 4c).  
Basal autophagy-mediated regulation of c-MET phosphorylation is linked to 
mTORC2  
We then investigated whether reduced RTK phosphorylation was associated with 
alterations of main signalling pathways. In this respect, we noted that upon 
doxycycline (Dox) treatment, CRC cells displayed reduced mTORC2-mediated 
phosphorylation of AKT (pAKT S473) relative to levels of total AKT (Figure 5a-c). 
Specifically, HCT-116 KRAS WT, DLD-1 KRAS WT and CaCo2 autophagy-
compromised cells displayed approximately 25%, 35% and 30% downregulation of 
pAKT S473, respectively. pAKT downregulation was more evident in the presence of 
KRAS G13D in HCT-116 and DLD-1 cells (35% and 65%, respectively; Figure 5a-c). 
Notably, pAKT S473 downregulation was confirmed in ATG7-deficient HCT-116 cells 
(Figure 5g). Reduced pAKT S473 was not associated with decreased 
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phosphorylation levels of the mTORC1 downstream target, S6 ribosomal protein 
(Figure 5d-f). Specifically, HCT-116 and DLD-1 KRAS WT autophagy-compromised 
cells showed increased rather than decreased S6 phosphorylation (~40% and ~15% 
respectively) when compared to their autophagy-proficient controls. In HCT-116 and 
DLD-1 KRAS G13D cells, pS6 ribosomal protein S240/244 levels remained 
unaffected upon autophagy downregulation. CaCo2 autophagy-compromised cells 
displayed a reduction in pS6 ribosomal protein S240/244 levels, albeit not statistically 
significant. Sustained activation of mTORC1 following autophagy suppression was 
further confirmed in ATG7 knockout HCT-116 cells (Figure 5h). Together, these data 
suggest that autophagy inhibition affects mTORC2 but not mTORC1 activity. 
Since inhibition of mTORC2-dependent AKT phosphorylation occurred also in cells 
where PI3K signalling is constitutively active (via PI3K activating mutations), we 
speculated that these signalling changes are upstream rather downstream the defect 
in RTK phosphorylation. Previous reports have shown that RTK signalling activates 
mTORC2 (ref 73) and vice versa mTORC2 promotes RTK activation.74 As a result, we 
investigated whether inhibition of mTORC2 could affect c-MET phosphorylation. 
Autophagy-proficient and-compromised cells were treated with 2nM of Torin2 
inhibitor that targets mTOR kinase activity and results in both mTORC1 and 
mTORC2 inhibition. Torin2 treatment downregulated mTORC2-mediated 
phosphorylation of AKT at S473 residue as well as phosphorylation of S6 ribosomal 
protein downstream of mTORC1 in both autophagy-proficient and autophagy-
compromised cells. Interestingly, Torin2 treatment decreased c-MET phosphorylation 
in autophagy-proficient cells to the similar extent to suppression of autophagy. 
Finally, Torin2 treatment did not further reduce c-MET phosphorylation in autophagy-
compromised conditions (Figure 6a). 
In an attempt to further confirm that basal autophagy-dependent regulation of 
mTORC2 controls c-MET phosphorylation, we investigated whether induction of 
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mTORC2 kinase activity could increase c-MET phosphorylation. To this end, we 
employed the mTORC1 inhibitor Rapamycin, which is known to upregulate mTORC2 
activity through inhibition of a mTORC1-mediated negative feedback loop.75-77 
Autophagy-proficient and-deficient HCT-116 cells were treated with Rapamycin and 
analysed at different time points. Rapamycin downregulated mTORC1 activity and 
led to increased mTORC2-mediated phosphorylation of AKT at S473. Notably, 
rapamycin-mediated mTORC2 upregulation resulted in accelerated phosphorylation 
of c-MET in autophagy-proficient cells but not in autophagy-deficient cells. (Figure 
6b). 
Collectively, our data suggest that basal autophagy regulates RTK activation at least 
in part in an mTORC2-dependent manner. 
Discussion 
Autophagy plays a complex role in cancer, which still remains not fully understood. It 
has been proposed by us and others that in established tumours autophagy plays a 
pro-survival role,28, 39, 41, 42, 45, 46, 57 in particular upon starvation or downstream 
inhibition of oncogenic kinase signalling, both of which result in inhibition of the main 
autophagy inhibitor, the PI3K/AKT/mTORC1 pathway. However, little is known on the 
role of autophagy and autophagy-like pathways in the presence of active 
PI3K/AKT/mTORC1 signalling in cancer cells, due to mutations in either PI3K or RAS 
pathway. As a model, we chose CRC, since PI3K and RAS pathways are often 
constitutively active, and RTK signalling is a factor implicated in cancer development 
and is being targeted clinically.55, 56, 58, 59 On one hand, we show that autophagy is not 
a relevant target for pharmacological intervention upon RTK inhibition when the 
PI3K/AKT pathway is constitutively active. On the other hand, we have disclosed a 
novel pathway, whereby KRAS and PI3K-independent basal autophagy positively 
regulates RTK activation through mTORC2 signalling. 
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EGFR targeted therapy has been characterised as a potent autophagy-inducing 
stimulus in cancer cells17, 19, 42, 44, 45, 48-50 via inhibition of the PI3K.42, 45, 46 However, we 
show here that constitutive activation of the PI3K/AKT pathway, downstream KRAS 
and/or PI3K activating mutations, blocks autophagy induction following EGFR 
inhibition in CRC cells. Our findings suggest that concomitant targeting of EGFR and 
autophagy in clinical settings would not be beneficial in KRAS or PI3K-mutated CRC 
patients. 
Interestingly, we found that all CRC cell lines utilised in this work exhibit basal 
autophagic flux irrespective of their PI3K or KRAS mutational status. Although earlier 
studies have suggested that autophagy can be regulated in an mTORC1-
independent manner,13-19 the role of basal autophagy in cancer remains elusive. We 
hypothesised that basal autophagy would not play a major degradative role in fed-
conditions, whereas it could affect cell signalling as previously reported.68, 69 
Specifically, we set out to investigate whether autophagy suppression could impact 
on RTK activation. To this end, we analysed RTK tyrosine phosphorylation upon 
knockdown of the essential autophagy gene ATG7. Interestingly, we found that basal 
autophagy suppression reduces RTK phosphorylation, including c-MET, c-RET and 
Dtk in CRC cells, in most cases independently of KRAS mutational status. We 
decided to focus on c-MET, since it has been proposed to play an oncogenic role in 
CRC52 and it has been implicated in the development of primary and acquired 
resistance of mCRC cells and patients to EGFR-targeted therapy.53, 54 Levels of total 
c-MET remained stable following basal autophagy suppression ruling out the 
possibility that the decrease in phosphorylation levels of c-MET is caused by 
decreased c-MET expression and/or degradation. Additionally, our findings suggest 
that basal autophagy-mediated regulation of RTK phosphorylation is not attributed to 
a general metabolic control of tyrosine-phosphorylation levels since the latter were 
not altered upon basal autophagy suppression and furthermore EGFR and IGF-IR β 
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phosphorylation was not altered following autophagy suppression. Therefore, we 
suggested that an unconventional non-catabolic function of basal autophagy is 
responsible for the regulation of RTK phosphorylation and c-MET specifically.  
The function of the autophagosome as a cell-signalling regulator in a non-catabolic 
manner has only recently been reported in the literature.68, 69 In this respect, we 
observed that basal autophagy suppression decreased mTORC2-mediated 
regulation of AKT in a non-degradative manner but did not alter mTORC1 activity, 
thus ruling out that autophagy-dependent regulation of mTORC2 is dependent on the 
previously reported mTORC1 negative feedback loop.78 The decrease in mTORC2 
signalling occurred in cells where the PI3K pathway is constitutively active due to 
PI3K activating mutations, suggesting that it was not caused by inhibition of RTK 
phosphorylation. Therefore, we asked whether reduced mTORC2 signalling 
responsible for the defect in RTK phosphorylation? Indeed, pharmacological 
inhibition of mTORC1/2 led to decreased c-MET phosphorylation in autophagy-
proficient but not autophagy-suppressed cells. Vice versa, rapamycin, which 
activates mTORC2, led to increased c-MET phosphorylation. Although we cannot 
exclude that decreased mTORC2 signalling in autophagy-impaired cells is in part 
due to inhibition of RTK signalling, our data suggest that autophagy positively 
mediates RTK phosphorylation via regulation of mTORC2 signalling. In this respect, 
mTORC2 activity has been previously described to directly regulate IGF-IR and IR 
phosphorylation in an mTOR kinase activity-dependent manner.74 Since there was 
no tight correlation between increased levels of p-c-MET and pAKT S473 upon 
rapamycin treatment (3 and 6 hour timepoints), autophagy may directly regulate c-
MET activation through mTORC2, potentially without a substantial involvement of 
AKT.  
One outstanding question is how autophagy regulates AKT and c-MET 
phosphorylation. We hypothesised that internalised c-MET could interact with 
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autophagy vesicles. Indeed, our findings show that c-MET partially colocalises with 
LC3B-positive structures intracellularly, whereas no colocalisation was observed with 
EGFR, which is not affected by autophagy inhibition in the phospho-RTK arrays. 
Interestingly, intracellular localisation of c-MET was not affected by autophagy 
suppression, suggesting that autophagic or autophagic-like vesicles do not regulate 
RTK internalisation but may represent signalling platforms regulating RTK 
phosphorylation. In this respect, AKT activity regulation through mTORC2 in 
intracellular compartments such as lysosomes has been previously described.79 
Furthermore, autophagy has been previously shown to affect ERK and AKT 
signalling.68, 69 
In overall, this work establishes an unconventional role of basal autophagy in 
regulation of RTK activation and suggest a bidirectional relationship between 
autophagy and RTK signalling: on one hand RTKs inhibit autophagy via mTORC1, 
while on the other hand autophagy positively modulate RTK signalling via mTORC2 
activation. Further work is needed to fully dissect the mechanisms by which 
autophagy controls RTK signalling in cancer cells.  
Materials and Methods 
Chemical compounds and drugs 
All chemical compounds and drugs were dissolved in an initial stock concentration 
and then in cell culture media to reach the final working concentration. Sterile 
conditions were followed throughout the preparation of all reagents. Fresh aliquots 
were used for each independent experiment. Chloroquine diphosphate salt (CQ) 
[#C6628, Sigma (Dorset, UK)] was dissolved in sterile Phosphate Buffered Saline 
(PBS) and was used at a concentration of 10 μM. Doxycycline hyclate (Dox) powder 
(#D9891, Sigma) was resuspended into sterile H2O and was used at the optimal 
working concentration of each CRC cell line (10 ng/ml for HCT-116; 100 ng/ml for 
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DLD-1 and CaCo2 cells). Dox was used for stimulation of shRNA expression in the 
pLKO-Tet-On inducible CRC cell lines. Clinical-grade Cetuximab and Gefitinib were 
used. Cetuximab (5 mg/ml) was obtained from Merck Serono (Darmstadt, Germany). 
All following drugs were dissolved in dimethyl sulfoxide (DMSO) (#D2650, Sigma). 
Clinical-grade Gefitinib [Iressa®; AstraZeneca (London, UK)] was used at a 
concentration of 1 μM and the AKT inhibitor vIII [#124018, Calbiochem®, Merck 
Millipore (Darmstadt, Germany)] was used in the indicated concentrations. Torin2 
(#475992, Calbiochem) was used at a concentration of 2 nM. Rapamycin [#R5000, 
LC Laboratories (Woburn, MA, USA)] was used in a concentration of 10 nM. In all 
experiments wherein cells were treated with compounds diluted in DMSO, the 
corresponding untreated conditions were treated with equal concentrations of DMSO.  
Plasmids 
A Dox-inducible system was used to knockdown ATG7 protein in CRC cells by using 
the Tet-pLKO-puro vector [Addgene plasmid #21915, Addgene (Cambridge, MA, 
USA)], established by Dmitri Wiederschain lab.80 The CRISPR/Cas9 system was 
used to delete ATG7 by using the lentiCRISPR vector (Addgene plasmid #52961), 
established by the Zhang lab.81 pLXSN and pLXSN_myrAKT plasmids were kindly 
provided by Dr Pablo Rodriguez-Viciana (University College London, UK). 
Antibodies 
Antibodies against human LC3B [1/1000; #2775, Cell Signaling Technology (Leiden, 
The Netherlands)], ATG7 (1/500; #2631, Cell Signaling Technology), β-actin (1/5000; 
#A5441, Sigma) and HGF [1/1000; #ab83760; Abcam (Cambridge, UK)] were diluted 
in 5% milk (w/v) 1X PBS - 0.1% Tween-20 (Sigma) in the corresponding 
concentration and used for immunoblotting. Antibodies against human pAKT S473 
(1/1000; #4060, Cell Signaling Technology), total AKT (1/1000; #9272, Cell Signaling 
Technology), total AKT (1/1000; #2920, Cell Signaling Technology), Calnexin 
(1/1000; #2433, Cell Signaling Technology), pS6 ribosomal protein S240/244 
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(1/1000; #2215, Cell Signaling Technology), total S6 ribosomal protein (1/500; 
#2317, Cell Signaling Technology), total IGF-IR beta (1/1000; #3027, Cell Signaling 
Technology), total EGFR (1/500; #2232, Cell Signaling Technology), p-c-MET 
Y1234/1235 (1/500; #3077, Cell Signaling Technology), total c-MET (1/1000; #8198, 
Cell Signaling Technology) and phosphotyrosine clone 4G10 (1/500-1/1000; #05321, 
Merck Millipore) were diluted in 5% BSA (w/v) 1X TBS – 0.1% Tween-20 (Sigma) in 
the corresponding concentration and used for immunoblotting. For 
immunoprecipitation studies the antibodies against human total c-MET (#8198, Cell 
Cell Signaling Technology), total EGFR (#4267, Cell Signaling Technology), total 
IGF-IR beta (#3027, Cell Signaling Technology) and normal IgG (#2729, Cell 
Signaling Technology) were used. For immunofluorescence experiments the 
antibodies against human LC3B [1/50; #0231-100/LC3-5F10, nanoTools 
Antikörpertechnik GmbH & Co. KG (Teningen, Germany)], total c-MET (1/150; 
#8198, Cell Signaling Technology) and total EGFR (1/50; #4267, Cell Signaling 
Technology) were used. Secondary antibodies used for immunoblotting were goat 
anti-rabbit IgG DyLight 800 [1/5000; #35571, Thermo Fisher Scientific (Waltham, MA, 
USA)], goat anti-mouse IgG DyLight 680 (1/5000; #35518, Thermo Fisher Scientific), 
ECL anti-rabbit IgG [1/5000; #NA934V, GE Healthcare UK Limited (Hatfield, UK)] 
and ECL anti-mouse IgG (1/5000; #NA931V, GE Healthcare UK Limited). Anti-rabbit 
IgG Alexa Fluor 555 (1/1000; #A31572, Invitrogen-Thermo Fisher Scientific) and anti-
mouse IgG Alexa Fluor 647 (1/1000; #A31571, Invitrogen-Thermo Fisher Scientific) 
secondary antibodies were used for immunofluorescence experiments. 
Cell culture  
HCT-116 and DLD-1 KRAS WT and G13D isogenic cell lines were kindly provided by 
Prof. Bert Vogelstein (Johns Hopkins University, USA). SW48 KRAS isogenic cell 
lines were purchased from the Horizon Discovery (Cambridge, UK). DiFi cells were 
kindly provided by Prof. Alberto Bardelli (University of Torino, Torino, Italy). Cells 
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were cultured in tissue culture dishes at 37oC in a humidified atmosphere of 5% CO2. 
HCT-116, DLD-1 and SW48 cells were maintained in McCoy’s 5A medium containing 
2 mM L-Glutamine. CaCo2 cells were maintained in Minimum Essential Medium 
(MEM) medium containing 2 mM L-Glutamine. DiFi cells were maintained in Ham’s 
F12 Nutrient mixture medium containing 1 mM L-Glutamine. HCT-116 CRISPR Ctrl 
and ATG7 cells as well as the human embryonic kidney cell line HEK-293T were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 4.5 
g/L D-Glucose and Sodium Pyruvate. The human embryonic kidney cell line, Phoenix 
A was maintained in Iscove’s Modified Dulbecco’s Medium (IMDM) containing 4.5 g/L 
D-Glucose and Sodium Pyruvate. All cell culture media were supplemented with 10% 
Fetal Bovine Serum (FBS, Thermo Fisher Scientific), and 1% Penicillin/Streptomycin 
(Gibco-Thermo Fisher Scientific). All inducible pLKO-Tet-On shRNA-expressing 
(shEGFP, shATG7-E8 and -G7) stable cell lines were maintained in corresponding 
medium supplemented with 10% Tet-Free Certified FBS (#16000-044, Lot number 
1221032, Thermo Fisher Scientific). Cell number counting and cell viability 
examination was conducted using the Vi-Cell XR machine and software (Beckman 
Coulter, Indianapolis, IN, USA). 
Transient transfection for small interfering RNAs (siRNAs) delivery 
Two different transfection reagents were used for the delivery of EGFR and LC3B 
siRNAs to CRC cell lines. SMARTpool: ON-TARGETplus EGFR siRNA (#L-003114-
00, GE Healthcare Dharmacon Inc, UK) and siRNA negative control (Scramble, GE 
Healthcare Dharmacon Inc, UK) were used in a concentration of 25 nM using 
DharmaFECT reagent 1 (#T-2001-02, GE Healthcare Dharmacon Inc, UK) in HCT-
116 cell line. Silencer select LC3B siRNA (#s37749 and #s224886, Thermo Fisher 
Scientific) and negative control (Scramble, #4390843, Thermo Fisher Scientific) were 
used in a concentration of 10 nM using Lipofectamine RNAiMAX reagent 
(#13778075, Thermo Fisher Scientific) in HCT-116 cells. Forward transfection 
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protocol was followed with both transfection reagents according to the protocol of 
each manufacturer. Cells were harvested 48 hours post-transfection by scraping and 
protein knock down was assessed using immunoblotting. 
Virus particle production  
The calcium phosphate transfection method was used to generate lenti- and retro-
virus particles by transfecting HEK 293T and Phoenix A cells with the corresponding 
plasmids, respectively. For pLKO-Tet-On shEGFP and shATG7 E8 or G7 -lentivirus 
particle production, 6 x 106  HEK 293T cells were plated in 15 cm dishes containing 
20 ml complete DMEM medium and were let to adhere overnight at 37o C. The 
following day, a triple co-transfection of HEK 293T cells with lentivirus 
packaging/envelope vectors and desired plasmid DNA was performed [7.2 μg of 
pCMV-VSV-G; 15.6 μg pCMV-HIV-1; 24 μg of shRNA encoding lentivirus vector 
(pLKO-Tet-On shEGFP or shATG7 E8 / G7)]. For CRISPR/Cas9 -Ctrl or -ATG7 
gRNAs -lentivirus particle production, 1.5 x 106  HEK 293T cells were plated in 10 cm 
dishes containing 10 ml complete DMEM medium and were let to adhere overnight at 
37o C. The following day, a triple co-transfection of HEK 293T cells with lentivirus 
packaging/envelope vectors and desired plasmid DNA was performed [7.5 μg of 
psPAX2; 4 μg of VSV-G; 10 μg of lentiCRISPR vectors encoding (Cas9 and Ctrl or 
ATG7 gRNAs)]. DNA-mixture was diluted in sterile nuclease free H2O containing 
10% (v/v) 2.5 M calcium chloride to a final volume of 1 ml. For retrovirus particle 
production, 2.5 x 106  Phoenix A cells were plated in 10 cm dishes containing 10 ml 
complete IMDM medium and were let to adhere overnight at 37oC. The following day, 
Phoenix A cells were co-transfected with 1.2 μg SARAIII retrovirus packaging vector 
and 20 μg desired plasmid DNA (pLXSN or pLXSN_myrAKT). DNA was diluted in 
sterile nuclease free H2O containing 25% (v/v) 1 M calcium chloride to a final volume 
of 1 ml. 
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For both lenti- and retro- virus production, the DNA-calcium chloride mixture was 
thoroughly mixed and allowed to equilibrate at room temperature for 30 min. 37oC 
pre-warmed 2X HEPES pH 7.05 buffer [280 mM NaCl; 10 mM KCl; 1.5 mM 
Na2HPO4; 12 mM D(+)-Glucose Monohydrate; 50 mM HEPES] was added to the 
DNA-calcium chloride solution in a ratio 1:1 and the mixture was thoroughly mixed for 
1 min. DNA-calcium chloride-HEPES mixture was added dropwise to each 15 cm/10 
cm dish containing HEK 293T cells or 10 cm dish containing Phoenix A cells. 
Transfection medium was replaced with normal culture medium after 8 hours. 
Transfected HEK 293T cells and transfected Phoenix A cells were let to incubate for 
additional 48 and 36 hours, respectively, when supernatants containing viral particles 
collected.  
Viral particles concentration by polyethylene glycol (PEG) precipitation was 
performed for pLKO-Tet-On shEGFP and shATG7 E8 or G7 -lentivirus particles and 
pLXSN_myrAKT/pLXSN retrovirus particles. Briefly, supernatants containing lenti- or 
retro- virus particles were centrifuged at 3000 g for 15 min to eliminate cells and 
cellular debris. Further cellular debris elimination was achieved by 0.45 μm PVDF 
filtration of the supernatant. 5X PEG pH 7.2 (50 mM PEG; 0.41 M NaCl; 0.2% Tris 1 
M, pH 7.5) solution was added to the supernatant containing the viral particles in a 
volume ratio 1:4 to concentrate the virus particles. Solution was refrigerated at 4oC 
overnight. The next day the concentrated virus particles were pelleted down through 
centrifugation at 1500 g for 30 min and PEG containing medium was discarded. Virus 
particle pellets were resuspended in sterile cold PBS in a volume ratio 50:1 and were 
aliquoted and stored at -80o C. Fresh concentrated virus particles aliquots were used 
in each independent viral transduction experiment. Tittering of virus was performed 
using antibiotic selection, as was previously described.80, 82 
For CRISPR/Cas9 -Ctrl or -ATG7 gRNAs -lentivirus particle production, lentivirus-
containing supernatant from HEK 293T cells was collected 48 and 72 hours after 
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transfection and filtered through a 0.45 μm PTFE filter membrane. Lentivirus-
containing supernatant was added fresh to the target cells. 
Generation of autophagy-compromised/-deficient and myristoylated AKT-
expressing CRC cell lines 
Viral transduction was used to generate stable inducible-expressing pLKO-Tet-On 
shRNA autophagy-proficient (shEGFP) and -compromised (shATG7 E8/G7) CRC 
cell lines, autophagy-proficient (CRISPR Ctrl) and -deficient (CRISPR ATG7) HCT-
116 cells as well as myristoylated AKT-expressing (pLXSN_myrAKT) and control 
(pLXSN) DiFi cells. 
For pLKO-Tet-On shRNA and pLXSN -expressing CRC cell lines, 1.0 x 105 cells were 
plated in 6-well plates and let to incubate overnight at 37o C. Cells were transduced 
with the appropriate volume of the corresponding concentrated virus based on virus 
tittering at an MOI of 10 in media containing 5 μg/ml polybrene. 24 hours later, virus-
containing medium was replaced by fresh complete medium and target cell lines 
were let to incubate for additional 24 hours. For CRISPR HCT-116 cells, 0.7 x 106 
cells were plated in 10 cm dishes and let to incubate overnight at 37o C. Cells were 
transduced with the lentivirus-containing supernatant (supernatant-48 hours after 
transfection) from HEK 293T cells supplemented with polybrene and let to incubate 
for 24 hours. The following day, fresh lentivirus-containing supernatant (supernatant-
72 hours after transfection) from HEK 293T cells was added to HCT-116 target cells 
for additional 24 hours. 
48 hours after viral transduction, antibiotic selection of transduced cell populations 
was performed using puromycin selection for pLKO-Tet-On-shRNA or CRISPR/Cas9 
expressing cells (0.5 μg/ml for HCT-116, 3 μg/ml for DLD-1 and 1.5 μg/ml for CaCo2 
cells) and neomycin selection for LXSN_myrAKT (750 μg/ml for DiFi cells) and 
control cells. Antibiotic-containing medium was replaced every two days for at least a 
week in order to generate stable cell lines. All experiments were conducted in the 
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absence of either puromycin or neomycin selection. The inducible downregulation of 
ATG7 protein was performed in the presence of Dox (10 ng/ml for HCT-116; 100 
ng/ml for DLD-1 and CaCo2 cells) for 5 days. 
Total cell protein extraction 
2.5 - 4 x 105 of CRC cells (depending on each CRC cell line) were plated in 6 cm 
tissue culture dishes and let to adhere for approximately 48 hours at 37o C until 
approximately 70% of confluence was reached. Drug treatment was applied under 
sterile conditions for the indicated incubation time and total cell protein extraction 
followed. Cell culture medium was removed and adhered cells were washed once 
with 1X PBS. 100 - 150 μl of RIPA Lysis Buffer [20 mM Tris pH 7.4; 150 mM NaCl; 1 
mM EDTA pH 8; 1 mM EGTA pH 8; 0.5% (w/v) Sodium Deoxycholate; 0.1% (v/v) 
sodium dodecyl sulfate (SDS); 1% (v/v) Nonidet P-40] or Non-Denaturing Lysis 
Buffer [20 mM Tris pH 7.4; 137 mM NaCl; 2 mM EDTA pH 8; 1% (v/v) Nonidet P-40] 
supplemented with protease inhibitors [10 μg/ml of each Pepstatin A (#P5318, 
Sigma), Aprotinin (#A6279, Sigma) and Leupeptin (#L8511, Sigma) or 1X of the 
protease inhibitor cocktail (#11697498001; Roche, Basel Switzerland)] and 
phosphatase inhibitors [1 mM Na3VO4 (#S6508, Sigma); 50mM NaF (#201154, 
Sigma)] was added to the cells on ice. Cell scraping was used to harvest cells from 
the culture dishes and cell lysates were transferred to microcentrifuge tubes. Cell 
lysates were incubated on ice for 30 min and then centrifuged at 13200 rpm for 15 
min at 4o C. Supernatants containing total cell protein extracts were transferred to 
new microcentrifuge tubes and kept on ice as long as the total cell protein 
concentration of extracts was quantified. For determination of total cell protein 
concentration, the BCA protein assay kit (#23227, Thermo Fisher Scientific) or 
Bradford assay [#500-0006, BioRad (Hertfordshire, UK)] were used according to 
instructions of the manufacturer. Following total cell protein concentration 
quantification, 5X protein loading buffer [10% (w/v) SDS; 50% (w/v) glycerol; 0.125% 
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(w/v) bromophenol blue; 250 mM Tris pH 6.8; 2 mM 2-mercaptoethanol] was added 
to cell lysates in a ratio 1:4 in order to yield a final concentration of 1X protein loading 
buffer to the cell extracts. Total cell extracts were boiled at 95o C for 5 min.  
 
Immunoblotting 
Equal concentration of total cell extracts (30 - 50 μg) were separated in 8%, 10%, 
15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) or Criterion™ TGX Stain-
Free™ Precast Gels (BioRad) as required and transferred for 21/2 hours onto 
nitrocellulose membrane in a wet blotter. 1X Running Buffer [0.186M Glycine; 0.02 M 
Trisma Base; 0.15% (v/v) SDS] was used for protein electrophoresis and 1X Transfer 
Buffer [0.186M Glycine; 0.02 M Trisma Base; 20% (v/v) Methanol] was used for 
protein transfer. Efficiency of protein transfer onto nitrocellulose membranes was 
examined by shortly incubating membranes in Ponceau S (Sigma) solution that 
reversibly removed by 1X PBS – 0.1% Tween-20 or 1X TBS – 0.1% Tween-20 
washes. Nitrocellulose membranes were blocked in 5% BSA (w/v) 1X TBS – 0.1% 
Tween-20 for phosphorylated studies and in 5% milk (w/v) 1X PBS – 0.1% Tween-20 
for all other studies with 1 hour incubation time. Immunodetection performed by 
incubating membranes with primary antibody overnight at 4oC and with the 
corresponding secondary antibody diluted in 5% milk (w/v) 1X PBS – 0.1% Tween-20 
for 1 hour. Protein expression was detected on medical X-Ray films using the 
Enhanced Chemiluminescence System (ECL) when HRP-conjugated secondary 
antibodies used. The Odyssey imaging System scanner (LI-COR Biotechnology - UK 
Ltd, Cambridge, UK) was used for detection of protein expression when fluorescent 
dye-conjugated secondary antibodies were used. LI-COR Odyssey software or Fiji 
(Image-J, NIH, MD, USA) software was used for densitometric analysis of protein 
bands detected either via LI-COR Odyssey Imaging System scanner or ECL, 
respectively.  
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Immunoprecipitation (IP) 
Lyophilised protein A Sepharose beads (#71-7090-00AF, GE Healthcare UK Limited) 
were hydrated in distilled H2O based on the instructions of the manufacturer and 
followed coupling of the protein A Sepharose beads with the antibodies used in IP 
studies. Briefly, the Sepharose protein A slurry was gently mixed by vortexing and 10 
μl of beads were washed twice with non-denaturing lysis buffer by intermediate 
centrifugations of 20 sec at 13200 rpm. Followed coupling of beads with the required 
volume of antibody in 300 μl of non-denaturing lysis buffer via rotation at 4oC for 4 
hours. Antibody-Sepharose A coupled beads were washed 4 times in non-denaturing 
lysis buffer containing protease and phosphatase inhibitors with intermediate 
centrifugation steps as abovementioned. IP was performed via incubating 500 - 1000 
μg of total cell protein extracts (into non-denaturing lysis buffer containing 
phosphatase and protease inhibitors) with 10 μl antibody-Sepharose A coupled 
beads in a total volume of 1000 μl with rotating for 3 hours at 4o C. Then beads were 
washed 4 times with 1000 μl non-denaturing lysis buffer containing phosphatase and 
protease inhibitors followed by centrifugation for 20 sec at 13200 rpm. The pellet was 
resuspended in 50 μl of 1X protein loading buffer, incubated at 95o C for 5 min and 
centrifuged at 13200 rpm for 1 min. The supernatant containing the 
immunoprecipitated proteins was then analysed using immunoblotting. 
 
Phospho-RTK array 
The human phospho-RTK array [#ARY001B (R&D Systems, Abingdon, UK)] was 
used for the determination of changes in phosphorylation of RTKs between 
autophagy-proficient and -compromised samples. The array was conducted with the 
specific reagents provided and based on the instructions of the manufacturer. Briefly, 
1.5 - 2 x 106 autophagy-proficient or -compromised cells (depending on the cell line 
used) were plated in 10 cm tissue culture dishes at day 3 of Dox treatment and let to 
adhere for another 48 hours at 37oC in the presence of Dox. Then cells were lysed 
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using Lysis Buffer 17 supplemented with protease and phosphatase inhibitors and 
protein quantification of total cell extracts was conducted using Bradford assay. 1500 
μg of total cell extracts was diluted into array buffer 1 to reach a volume of 1.5 ml and 
samples of each autophagy-proficient or -compromised condition were applied onto 
the nitrocellulose membrane with the RTK-captured antibodies. Followed overnight 
incubation at 4oC on a rocking platform shaker and the next day nitrocellulose 
membranes were washed and incubated with a pan anti-phospho-tyrosine antibody 
conjugated to HRP in a dilution 1:5000 for 2 hours at room temperature. The 
phosphorylated tyrosines on RTKs were detected by chemilluminescence using X-
ray Films and multiple exposure times (20 sec - 10 min) were used to detect the 
majority of RTKs. Nitrocellulose membranes incubated with autophagy-proficient or -
compromised lysates were placed into the same autoradiography cassette and 
developed concomitantly to allow comparison between conditions. For densitometric 
analysis of phospho-RTK array results, X-ray films were scanned in high resolution 
(1200 dpi) and the GS-800 Calibrated Densitometer (BioRad) was used to quantify 
the intensity of each independent RTK spot. Numerical results were analysed by 
determining the average signal (pixel intensity) of the pair of duplicate spots 
presenting each RTK and followed by subtraction of an averaged background signal 
for each RTK independently. Differences in RTK phosphorylation were determined 
by comparing phosphorylation of RTKs between autophagy-proficient and -
compromised cells.  
Sulforhodamine B (SRB) Cell Proliferation / Survival assay 
Using the Sulforhodamine B (SRB) colorimetric assay, cell proliferation/survival was 
assessed upon drug treatments. SRB assay is used for cell density determination by 
measuring cellular protein content.83 3000 cells / 200 μl of medium were seeded in 
each well of flat 96-well plates. 48 hours post-seeding cells were treated with the 
indicated concentration of Cetuximab -/+ 10 μM CQ for 87 hours at 37o C. A separate 
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control plate that has been seeded with the same number of cells was fixed before 
treatment and considered as the “day 0” control. The control plate was stored at 
room temperature and processed along with the experimental plates. Briefly, media 
was aspirated from the wells and cells fixed in 10% (w/v) of Trichloroacetic acid for 
20 min at 4o C. Cells stained in 0.4% (w/v) SRB solution for 20 min at room 
temperature. Traces of the unbound dye were removed by washing cells 5 times with 
1% (w/v) Trichloroacetic acid and the plates air-dried overnight. The dye was 
solubilized with 10 mM Tris base (pH 10.5) for 30 min at room temperature and 
absorbance was measured at 540 nm. Numerical results were analysed and 
expressed as % of control cell growth as previously described.83  
Immunofluorescence (IF) 
6 x 104 HCT-116 cells were plated on sterile glass coverslips in 24-well plates and let 
to adhere for 48 hours at 37oC. Cells were treated with 10 μM CQ for 6 hours. Cells 
were fixed with 4% PFA for 15 min, followed incubation in 100% methanol for 10 min 
in -20oC and finally three washes in 1X PBS (5 min each). Fixed cells were blocked 
in blocking buffer (5% BSA in 1X PBS supplemented with 0.3% Triton-X100) for 1 
hour at room temperature and were stained with the corresponding primary antibody 
overnight at 4o C. After primary antibody incubation, cells were washed 3 times with 
1X PBS – 0.1% Tween-20 to remove traces of unspecifically bound antibody and 
followed incubation in dark with secondary fluorescent-conjugated antibodies at room 
temperature for 1 hour. Traces of secondary antibody were removed by washing 3 
times with 1X PBS – 0.1% Tween-20. Nuclear staining was performed via incubating 
cells with Hoechst dye in a dilution 1:5000 in PBS for 30 min. Coverslips were 
mounted on microscope slides, let to dry and stored at 4o C. Images were acquired 
using a Zeiss LSM 700 (Carl Zeiss Microscopy Ltd, Cambridge, UK) confocal 
microscope using x63 objective/1.4 numerical aperture. Z-stack images thickness 
was set to 0.4 μm and images in each experiment were acquired at same settings 
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and exposure times. Post-acquisition brightness adjustments were identical between 
images of the same experiment and performed in Adobe Photoshop (Adobe 
Systems, San Jose, CA, USA). Quantification of intracellular c-MET was performed 
by manually specifying the intracellular region of interest (ROI) of every cell in a 
single z-stack image using Fiji software. Plasma membrane staining was excluded 
from quantification analysis.  
Determination of KRAS and PIK3CA mutational status 
2 x 106 CRC cells were harvested by trypsinisation, pelleted down and subjected to 
RNA extraction by using the RNeasy Plus Mini Kit [#74134, Qiagen Ltd, 
(Manchester, UK)]. The procedure conducted based on the instructions of the 
manufacturer. Total RNA was eluted in 30 μl RNase-free H2O. The high capacity 
cDNA reverse transcription kit (#4368814, Thermo Fisher Scientific) was used to 
retrotranscribe 1 μg of RNA isolated from CRC cells based on the instructions of the 
manufacturer. Briefly, reverse-transcription PCR reaction was performed in a total 
volume of 20 μl containing RNA and 2X RT mastermix (10X RT buffer; 25X dNTP 
Mix; 10X RT random primers; multiscribe reverse transcriptase; RNA inhibitors; 
nuclease-free H2O) in a 1:1 ratio. The conditions of reverse-transcription PCR were 
25o C for 10 min, 37o C for 120 min and 85o C for 5 min. 
The newly synthesized cDNA was used with each of the following primer pairs for 
KRAS and PIK3CA mutational status determination using PCR. 
KRAS_Exon1-2 forward primer: AGGCCTGCTGAAAATGACTGAA 
KRAS_Exon3 reverse primer: GGTCCCTCATTGCACTGTACTCC 
PIK3CA_Exon15-16 forward primer: ATGATTTACGGCAAGATATGC 
PIK3CA_Exon20 reverse primer: TCAGTTCAATGCATGCTGTTT 
PIK3CA_Exon4-5 forward primer: AAGATCTATGTTCGAACAGGT 
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PIK3CA_Exon11-10 reverse primer: ACATCTGGGCTACTTCATCTC 
PCR reactions were performed in a total volume of 50 μl, containing 5 μM of each 
forward and reverse primers, 46 μl PCR Master Mix (MgCl2 buffer; dNTPs; nuclease-
free H2O) with 1 Unit of FastStart Taq DNA Polymerase (Roche). The conditions of 
PCR reactions were for KRAS fragments: 35 cycles of 95o C for 1 min, 62.1o C for 45 
sec and 72o C for 45 sec with an initial denaturation cycle of 95o C for 5 min and a 
final extension cycle of 70o C for 7 min; and PIK3CA fragments: 35 cycles of 95o C for 
1 min, 60o C for 45 sec and 72o C for 1 min with an initial denaturation cycle of 95o C 
for 5 min and a final extension cycle of 72o C for 10 min. Fractionation of PCR 
products was performed by electrophoresis in 1 - 1.5% Agarose (#A9539, Sigma) / 
TAE gel containing ethidium bromide. DNA was mixed with 5X DNA Loading Buffer 
[100 mM Tris pH 8; 10 mM EDTA pH 8; 50% Glycerol; 0.5% (w/v) bromophenol blue] 
and electrophoresed at 100 V for approximately 30 min. DNA bands were visualised 
under ultraviolet light. Purification of DNA fragments from Agarose / TAE gel was 
performed by GeneJet Gel Extraction kit (#K0691, Thermo Fisher Scientific) following 
the instructions of the manufacturer. Sequencing of PCR amplified fragments was 
performed in the UCL CI sequencing facility by using the appropriate primers. 
Sequencing results were visualised using Finch TV software and were further 
analysed by using the EMBOSS Pairwise Alignment Algorithm from the EMBL-EBI 
Database (http://www.ebi.ac.uk/Tools/emboss/align/). 
Cloning of shRNA oligos to pLKO-Tet-On vector 
To generate shRNA pLKO-Tet-On expressing plasmids against ATG7 protein, single-
stranded oligos encoding the desired shRNA sequence were designed based on 
previously published shATG7 sequences.29 ATG7 single-stranded oligo sequences 
were incorporated with cloning overhangs and loop sequence. ATG7 single-stranded 
oligos firstly annealed and then cloned into the inducible lentiviral pLKO-Tet-On 
vector by following the previously described protocols.80, 82 For the annealing of 
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single-stranded oligos, 11.25 μl of each forward and reverse oligo (100 μM) were 
mixed with 2.5 μl of 10X annealing buffer (1 M NaCl; 100 mM Tris-HCl, pH 7.4) and a 
PCR program was used to perform the reaction. The conditions of the PCR program 
used are: 10 min at 98o C, 5 min at 95o C, 5 min at 90o C, 5 min at 88o C, 5 min at 85o 
C, 5 min at 80o C, 5 min at 78o C, 5 min at 75o C, 5 min at 70o C, 5 min at 68o C, 5 min 
at 65o C, 5 min at 60o C, 5 min at 58o C, 5 min at 55o C, 5 min at 50o C, 5 min at 45o C, 
5 min at 40o C, 10 min at 37o C and cooling down to 4o C. The annealed oligo mixture 
was diluted in 0.5X of annealing buffer in a ratio 1:400 and ligated to the cloning sites 
of pLKO-Tet-On vector created by AgeI (Promega Corp., Madison, WI, USA) /EcoRI 
(Roche) digestion in Multicore buffer (Promega). The reaction was incubated at 37o C 
for 11/2 hours and the restriction digestion products were visualised on 1% Agarose / 
TAE gel. Followed purification of the digested pLKO-Tet-On vector from Agarose / 
TAE gel by following the instructions of the manufacturer (GeneJet Gel Extraction kit; 
#K0691; Thermo Fisher Scientific). Ligation reaction was performed in a total volume 
of 10 μl, containing double-stranded oligos, the digested pLKO-Tet-On vector, 2X 
Rapid Ligase buffer (#C671B, Promega) and T4 DNA ligase (#M180B, Promega). 
Ligation mixture was incubated at room temperature for 15 min and transformation of 
ligated products in Stbl3 cells followed. Bacteria colonies were grown to enable 
purification of plasmid DNA using the JetStar 2.0 Plasmid Purification Kit (Genomed, 
Löhne, Germany) according to the instructions of the manufacturer. Verification of 
the inserted oligos was conducted by sequencing. 
 
Cloning of guide RNA sequences to lentiCRISPR vector 
The target guide RNA sequence against human ATG7 was designed based on the 
Zhang Lab GeCKO website http://www.genome-engineering.org/gecko/. Additionally, 
the CRISPR design tool software http://crispr.mit.edu/ was used for the identification 
of suitable target sites for guide RNA sequence design against ATG7. For targeting 
ATG7, the exon 2 coding sequence: GAAGCTGAACGAGTATCGGC  was used. For 
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control (Ctrl), the gRNA sequence GTAGCGAACGTGTCCGGCGT was used, 
generated by Wang et al.84 The abovementioned oligo-sequences integrated with 
specific overhangs for cloning were ordered. 
To clone the Ctrl and ATG7 gRNA sequences, 5 μg of the lentiCRISPR vector was 
enzymatically digested with BsmBI (NEB) using Buffer 3.1 (NEB) for 2 hours at 37° 
C. 10 μM of each single-stranded forward and reverse -gRNA oligo was 
phosphorylated using T4 Polynucleotide Kinase (Cambio) at 37° C for 30 min (based 
on the instructions of the manufacturer) and then annealed by heating at 95° C for 5 
min and cooling down to 25° C at 5° C/min. The annealed gRNA oligos were diluted 
in a 1/200 concentration using ddH2O and ligated into 50 ng gel purified vector 
(QIAquick Gel Extraction Kit; #28704, Qiagen). For ligation reaction, the Rapid DNA 
Ligation kit (#11 635 379 001, Roche) was used at room temperature for 15min 
according to the instructions of the manufacturer. Followed transformation of ligated 
products in Stbl3 cells. Bacteria colonies were grown and purification of plasmid DNA 
from mini-cultures was performed. Verification of gRNA cloning was conducted by 
sequencing using .the LKO.1 forward primer: 5'- GACTATCATATGCTTACCGT-3'. 
Positive clones were amplified in large-volume bacteria cultures and plasmid DNA 
was isolated for long-term storage and use. 
 
Statistical analysis 
Means of at least three independent experiments unless otherwise stated were 
statistically analysed using GraphPad Prism v5 (GraphPad Software, Inc, La Jolla, 
CA, USA). Determination of statistical significance in single-comparisons was 
performed using two-tailed unpaired Student’s t-test with Welch’s correction and in 
multiple means comparisons using one-way or two-way ANOVA followed by the 
Bonferroni post-test. 
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Figure legends 
Figure 1 The majority of CRC cells are incompetent for autophagy induction 
following EGFR targeted therapy but they have basal levels of autophagy. (a-e) 
Autophagy induction following EGFR targeted therapy in CRC cells. CRC cells [(a) 
DiFi; (b) HCT-116; (c) CaCo2; (d) DLD-1 and (e) SW48] were treated with 50 or 100 
μg/ml Cetuximab +/- 10 μM CQ for 24 hours and total cell lysates were analysed 
using immunoblot for LC3B protein. Autophagy induction in untreated and 
Cetuximab-treated CRC cells in the presence and/or absence of CQ was assessed 
by accumulation of LC3-II levels over LC3-I levels. Bar plots represent densitometric 
analysis of LC3-II/LC3-I levels normalised to β-actin or calnexin (n=1). (f-i) 
Monitoring of basal autophagic flux in CRC cell lines. CRC cells [(f) HCT-116; (g) 
DLD-1; (h) CaCo2 and (i) DiFi] were treated +/- 10μM CQ for 6 hours and total cell 
lysates were analysed using immunoblot for LC3B protein. Accumulation of LC3-II 
over LC3-I band following CQ treatment depicts basal autophagic flux of CRC cells 
(n=1). Levels of β-actin or calnexin were used as immunoblot loading controls. 
 
Figure 2 Genetic modulation of autophagy reduces phosphorylation of RTKs in HCT-
116 KRAS WT and G13D isogenic cells. Autophagy-proficient (shEGFP) and 
autophagy-compromised (shATG7 E8) cells were treated with 10 ng/ml Dox for 5 
days to efficiently downregulate ATG7 protein and total cell lysates were subjected to 
phospho-RTK array analysis. (a) Immunoblots presented are from one complete 
experiment, processed simultaneously for all conditions examined and are 
representative of two independent experiments for KRAS WT and one experiment for 
KRAS G13D cells. Arrow indicates increased exposure time used to develop 
immunoblots. (b-c) Bar plots depict densitometric quantification of phospho-RTK 
array spots. Bars represent mean ± standard deviation. Black boxes indicate RTKs 
found to be deregulated upon autophagy suppression in both HCT-116 KRAS WT (b) 
and G13D (c) cells. 
 
Figure 3 Autophagy inhibition downregulates c-MET RTK activation in CRC cells. (a) 
Total c-MET immunoprecipitation showing reduced c-MET phosphorylation in 
autophagy-compromised HCT-116 KRAS WT cells. Autophagy-proficient (shEGFP) 
and -compromised (shATG7 E8) cells 5 days after 10 ng/ml Dox treatment were 
lysed and total c-MET protein subjected to immunoprecipitation. Immunoprecipitated 
c-MET phosphorylation was assessed using immunoblotting for p-Tyrosine 4G10 
antibody. Total c-MET was used to examine immunoprecipitation efficiency and 
loading. β-actin was used as loading control of total cell lysates (n=1). (b) 
Immunoblot showing reduced phosphorylation of c-MET Y1234/1235 catalytic 
subunit residues in autophagy-compromised HCT-116 KRAS WT and G13D cells. 
Autophagy-proficient (shEGFP) and -compromised (shATG7 E8) cells were treated 
with 10 ng/ml Dox for 5 days and total cell lysates were subjected to immunoblotting 
for ATG7, p-c-MET Y1234/1235 and total c-MET protein levels. β-actin was used as 
loading control. Bar plots represent densitometric quantification of p-c-MET 
Y1234/1235 relative to total c-MET protein. The bars represent mean ± standard 
deviation of n=3 (HCT-116 KRAS WT) and n=2 (HCT-116 KRAS G13D); * p<0.05. 
Unpaired Student’s t-test statistical analysis was used for HCT-116 KRAS WT cells 
(n=3). (c) Immunoblot showing reduced phosphorylation of c-MET Y1234/1235 
catalytic subunit residues in autophagy-deficient HCT-116 cells. Total cell lysates of 
autophagy-proficient (CRISPR Ctrl) and -deficient (CRISPR ATG7) cells were 
subjected to immunoblotting for ATG7, p-c-MET Y1234/1235 and total c-MET protein 
levels. Bar plot represents densitometric quantification of p-c-MET Y1234/1235 
relative to total c-MET protein. The bars represent mean ± standard deviation of n=4; 
*** p<0.001. Unpaired Student’s t-test statistical analysis was used. (d) Immunoblot 
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showing reduced phosphorylation of c-MET Y1234/1235 catalytic subunit residues in 
autophagy-compromised CaCo2 cells. Autophagy-proficient (shEGFP) and -
compromised (shATG7 E8 and G7) cells were treated with 100 ng/ml Dox for 5 days 
and total cell lysates were subjected to immunoblotting for ATG7, p-c-MET 
Y1234/1235 and total c-MET protein levels. Bar plots represent densitometric 
quantification of p-c-MET Y1234/1235 relative to total c-MET protein. The bars 
represent mean ± standard deviation of n=2. 
 
Figure 4 c-MET colocalises with LC3B positive intracellular structures but basal 
autophagy suppression does not alter c-MET intracellular accumulation. (a) 
Representative immunofluorescence images showing total c-MET colocalising with 
LC3B positive intracellular structures only in autophagy-proficient conditions. 
Autophagy-proficient (shEGFP) HCT-116 KRAS WT cells were treated with 10 ng/ml 
Dox for 5 days. At day 5 of Dox treatment, cells were treated with 10 μM CQ for 6 
hours and then fixed. Autophagy-proficient (Ctrl) and -deficient (ATG7) HCT-116 
CRISPR cells were treated with 10 μM CQ for 6 hours and then fixed. Cells were 
stained for total c-MET (green), LC3B (red) and nucleus (Hoechst dye-blue). Scale 
bar corresponds to 10 μm. (b) Representative immunofluorescence image showing 
total EGFR not colocalising with LC3B positive intracellular structures. Autophagy-
proficient (shEGFP) HCT-116 KRAS WT cells were treated with 10 ng/ml Dox for 5 
days. At day 5 of Dox treatment, cells were treated with 10 μM CQ for 6 hours and 
then fixed. Cells were stained for total EGFR (green), LC3B (red) and nucleus 
(Hoechst dye-blue). Scale bar corresponds to 10 μm. (c) Intracellular c-MET 
accumulation upon autophagy suppression. HCT-116 KRAS WT autophagy-
proficient (shEGFP) and -compromised (shATG7 E8) cells were treated with 10 
ng/ml Dox for 5 days. 6 hours prior to fixation cells were treated with 10 μM CQ. Cells 
were stained for total c-MET (green) and nucleus (Hoechst dye-blue). Bar plot 
depicts average intensity of intracellular c-MET/cell by using Fiji software (ImageJ). 
Quantification of intracellular c-MET was performed by manually specifying the 
intracellular region of interest (ROI) of every cell in a single z-stack image. Plasma 
membrane staining was excluded from quantification analysis. Bars represent mean 
± s.e.m. of n= 40 shEGFP and n= 34 shATG7 E8 cells from three independent 
experiments. Images were acquired using a Zeiss LSM 700 confocal microscope. 
Post-acquisition brightness adjustments were identical between images of the same 
experiment and performed in Adobe Photoshop. White arrows show intracellular c-
MET accumulation. Scale bar corresponds to 10 μm. 
 
Figure 5 Genetic modulation of autophagy impairs mTORC2-mediated 
phosphorylation of AKT. Autophagy-proficient and -compromised HCT-116 and DLD-
1 KRAS WT and G13D isogenic cell lines as well as CaCo2 cells were treated with 
Dox for 5 days and total cell lysates were subjected to immunoblot analysis for the 
indicated proteins. (a-c) ATG7 knockdown regulates AKT phosphorylation at S473 
residue in CRC cells. Total cell lysates of autophagy-proficient (shEGFP) and -
compromised (shATG7 E8) cells [(a) HCT-116, n=4; (b) DLD-1 n=3 and (c) CaCo2, 
n=4] were subjected to immunoblot analysis for ATG7, pAKT S473 and total AKT 
levels. β-actin was used as loading control. Bar plots represent densitometric 
analysis of pAKT S473 relative to total AKT. The bars represent mean ± standard 
deviation; ns= non-statistically significant, * p<0.05, ** p<0.01 and *** p<0.001. Two-
way ANOVA statistical analysis was used for (a) and (b) and unpaired Student’s t-
test for (c). (d-f) Reduced AKT phosphorylation in autophagy-compromised cells 
does not regulate mTORC1 activation. Total cell lysates of autophagy-proficient 
(shEGFP) and -compromised (shATG7 E8) cells [(d) HCT-116 KRAS WT n=3 and 
KRAS G13D n=2; (e) DLD-1, n=2 and (f) CaCo2, n=3] were subjected to immunoblot 
analysis for ATG7, pS6 ribosomal protein S240/244 and total S6 ribosomal protein 
levels. Phosphorylation levels of S6 ribosomal protein depict activation level of 
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mTORC1. β-actin and total AKT were used as loading controls. Bar plots represent 
densitometric analysis of pS6 ribosomal protein relative to total S6 ribosomal protein 
or loading control. The bars represent mean ± standard deviation; ns= non-
statistically significant. Unpaired Student’s t-test statistical analysis was used for (d) 
and (f) cells. (g-h) HCT-116 CRISPR ATG7 knockout cells confirm pAKT S473 and 
mTORC1 findings observed by downregulation of ATG7. Total cell lysates of 
autophagy-proficient (Ctrl) and -deficient (ATG7) HCT-116 cells were subjected to 
immunoblot analysis for ATG7, pAKT S473 and pS6 ribosomal protein S240/244 
relative to total AKT and total S6 ribosomal protein levels, respectively. Bar plots 
represent densitometric analysis of pAKT S473 relative to total AKT (g) and pS6 
ribosomal protein relative to total S6 ribosomal protein (h). The bars represent mean 
± standard deviation; ns= non-statistically significant, * p<0.05. Unpaired Student’s t-
test statistical analysis was used (n= 4). 
 
Figure 6 Basal autophagy-mediated regulation of c-MET phosphorylation is linked 
with mTORC2 activation levels. (a) mTOR kinase inhibition in autophagy-proficient 
cells reduces phosphorylation levels of c-MET. Autophagy-proficient (shEGFP) and -
compromised (shATG7 E8) HCT-116 KRAS WT cells were treated with 10 ng/ml Dox 
for 5 days. At day 5 of Dox treatment, cells were treated with 2 nM of the Torin 2 
inhibitor for 6 hours and total cell lysates were subjected to immunoblotting for the 
indicated proteins. Bar plots represent densitometric quantification of p-c-MET 
Y1234/1235 relative to total c-MET protein and pAKT S473 relative to total AKT 
protein. The bars represent mean ± standard deviation of n=4; ns=non-significant; *** 
p<0.001. Two-way ANOVA statistical analysis was used. (b) Rapamycin treatment 
increases c-MET phosphorylation only in autophagy-proficient cells. Autophagy-
proficient (Ctrl) and -deficient (ATG7) HCT-116 CRISPR cells were treated with 10 
nM of Rapamycin for 3, 6 and 24 hours and total cell lysates were subjected to 
immunoblotting for the indicated proteins. Bar plots represent densitometric 
quantification of p-c-MET Y1234/1235 relative to total c-MET protein and pAKT S473 
relative to total AKT protein (n=1). 
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